Patents Assigned to Mor Research Applications, Ltd.
-
Publication number: 20080138331Abstract: A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.Type: ApplicationFiled: October 2, 2007Publication date: June 12, 2008Applicants: Mor Research Applications, Ltd., Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Peter Altevogt, Mina Fogel
-
Publication number: 20080051440Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows am efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.Type: ApplicationFiled: August 3, 2007Publication date: February 28, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080051439Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.Type: ApplicationFiled: August 3, 2007Publication date: February 28, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Patent number: 7332582Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: GrantFiled: November 19, 2004Date of Patent: February 19, 2008Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Patent number: 7329639Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: GrantFiled: April 27, 2006Date of Patent: February 12, 2008Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20080025980Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: ApplicationFiled: September 12, 2007Publication date: January 31, 2008Applicants: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Jones, Leah Klapper
-
Publication number: 20080004324Abstract: Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080004254Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080003306Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20080004322Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.Type: ApplicationFiled: August 3, 2007Publication date: January 3, 2008Applicant: Mor Research Applications Ltd.Inventor: Nir Barak
-
Publication number: 20060276390Abstract: Compositions and methods for the treatment of graft rejection associated with transplantation of tissues and organs include combined treatment involving at least one agent selected from Copolymer 1, a copolymer 1-related heteropolymer or an ordered peptide in combination with at least one additional known immunosuppressive agent. Compositions and methods for the treatment of graft rejection using ordered peptides or ordered copolymer 1-related heteropolymers as monotherapy are also provided.Type: ApplicationFiled: August 4, 2006Publication date: December 7, 2006Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., MOR RESEARCH APPLICATIONS LTD.Inventors: Rina Aharoni, Ruth Arnon, Michael Sela, Alex Yussim
-
Patent number: 7122372Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: GrantFiled: April 9, 2004Date of Patent: October 17, 2006Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20060210573Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: ApplicationFiled: April 27, 2006Publication date: September 21, 2006Applicants: Curetech Ltd.,, Mor-Research Applications Ltd.,Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20060166204Abstract: Specific PON1 and ACHE alleles segregate in linkage, forming an haplotype which directly correlates with higher susceptibility to develop Parkinson's Disease (PD). This PD-susceptibility haplotype is herein presented as a tool for predicting the risk of developing Parkinson's Disease and its severity, both for an individual and for the population in general. Thus, the present invention provides the use of said PD-susceptibility haplotype in diagnostic and screening methods.Type: ApplicationFiled: September 24, 2003Publication date: July 27, 2006Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Mor Research Applications Ltd., Ben-Gurion University of Negev, Research & Development AuthorityInventors: Hermona Soreq, Liat Ben-Moyal, Boris Bryk, Alon Friedman
-
Publication number: 20060099209Abstract: The invention concerns novel DNA and amino acid sequences of monoclonal antibodies. (mAbs) raised against lymphoblastoid cells and peptides to which the mAbs bind to. The invention also concerns diagnostic assays using said antibodies or peptides for detecting individuals with a high probability of having a malignant disease and, at times, for detecting an individual having a specific malignant disease. The invention further concerns pharmaceutical compositions comprising the mAbs or peptides of the invention for use in the treatment of various malignant diseases as well as methods for the treatment of malignant diseases using the mAbs or peptides of the invention.Type: ApplicationFiled: December 23, 2005Publication date: May 11, 2006Applicant: MOR RESEARCH APPLICATIONS LTD.Inventors: Britta Hardy, Abraham Novogrodsky
-
Publication number: 20050017179Abstract: The invention presents methods of using Fourier transform infrared microspectroscopy (FTIR-MSP) for distinguishing between normal and abnormal human cells and for diagnosis and digital staging of human cells on biopsied samples. The invention further presents computational methods employing neural network (NN) based classifiers for diagnosis and digital staging of adenomatous polyp and malignant tissue types of biopsied samples of human cells.Type: ApplicationFiled: May 14, 2004Publication date: January 27, 2005Applicants: BEN-GURION UNIVERSITY OF THE NEGEV, MOR RESEARCH APPLICATIONS LTD.Inventors: Shaul Mordechai, Jed Goldstein, Shmuel Argov, Hugo Guterman, Jagannathan Ramesh
-
Publication number: 20040197832Abstract: A method is provided for determining the gender and/or chromosomal abnormality, e.g. chromosomal aneuploidy of a fetus comprising identifying fetal cells in a transcervical cell sample obtained from a pregnant woman, for example with an antibody specific to the HLA-G antigen expressed only by extravillous trophoblast cells, and then subjecting the identified fetal cells to fluorescence in situ hybridization (FISH) with one or more probes for detecting the sex of the fetus or a chromosomal abnormality such as a monosomy, a trisomy or a polyploidy, e.g. triploidy.Type: ApplicationFiled: April 3, 2003Publication date: October 7, 2004Applicant: Mor Research Applications Ltd.Inventors: Aliza Amiel, Moshe D. Fejgin
-
Publication number: 20030216316Abstract: Pharmaceutical compositions comprising erythropoietin are provided for treatment of cancer, particularly for treatment of multiple myeloma. Erythropoietin was found to be effective for inhibition of tumor growth, triggering of tumor regression, stimulation of the natural immunological defense against cancer and/or inhibition of cancer cell metastasis.Type: ApplicationFiled: March 5, 2003Publication date: November 20, 2003Applicants: Yeda Research and Development Co. Ltd., MOR Research Applications Ltd.Inventors: Nechama Haran-Ghera, Moshe Mittelman, Alpha Peled
-
Patent number: 6579525Abstract: Pharmaceutical compositions comprising erythropoietin are provided for treatment of cancer, particularly for treatment of multiple myeloma. Erythropoietin was found to be effective for inhibition of tumor growth, triggering of tumor regression, stimulation of the natural immunological defense against cancer and/or inhibition of cancer cell metastasis.Type: GrantFiled: October 5, 2000Date of Patent: June 17, 2003Assignees: Yeda Research and Development Co. Ltd., Mor Research Applications Ltd.Inventors: Nechama Haran-Ghera, Moshe Mittelman, Alpha Peled
-
Patent number: 6503246Abstract: An intralesional method for treating a hypertrophic scar or keloid using a cryoprobe. The method comprises: (a) inserting the cryoprobe into the hypertrophic scar or keloid so that the cryoprobe is positioned within the hypertrophic scar or keloid; and (b) introducing a cryogen into the cryoprobe thereby freezing the hypertrophic scar or keloid. The cryoprobe has a sealed distal end comprising a cutting tip. Also disclosed is a cryoprobe comprising an elongated, uninsulated housing having a sealed distal end and a proximal end. The housing comprises therein a cryogen inlet tube. The cryoprobe further comprises a cutting tip at the distal end of the housing and a cryogen vent adjacent to the proximal end and in fluid communication with the interior of the housing.Type: GrantFiled: July 5, 2000Date of Patent: January 7, 2003Assignees: Mor Research Applications Ltd., Cleanetica Ltd.Inventors: Yaron Har-Shai, Micha Amar